| Item Type | Name |
|
Academic Article
|
Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor.
|
|
Concept
|
Protein Kinase Inhibitors
|
|
Concept
|
Mitogen-Activated Protein Kinase Kinases
|
|
Concept
|
Proto-Oncogene Proteins c-akt
|
|
Academic Article
|
Determinants of rapamycin sensitivity in breast cancer cells.
|
|
Academic Article
|
Intracellular signaling in tumor and endothelial cells: The expected and, yet again, the unexpected.
|
|
Academic Article
|
eIF4E knockdown decreases breast cancer cell growth without activating Akt signaling.
|
|
Academic Article
|
The effect of leucine restriction on Akt/mTOR signaling in breast cancer cell lines in vitro and in vivo.
|
|
Academic Article
|
PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors.
|
|
Academic Article
|
Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.
|
|
Academic Article
|
Mammalian target of rapamycin.
|
|
Academic Article
|
Rapamycin regulates the phosphorylation of rictor.
|
|
Academic Article
|
Comparison of Akt/mTOR signaling in primary breast tumors and matched distant metastases.
|
|
Academic Article
|
Deciphering the role of PI3K/Akt/mTOR pathway in breast cancer biology and pathogenesis.
|
|
Academic Article
|
Targeting the PI3-kinase/Akt/mTOR signaling pathway.
|
|
Academic Article
|
Functional proteomics characterization of residual triple-negative breast cancer after standard neoadjuvant chemotherapy.
|
|
Academic Article
|
PD-L1 expression in triple-negative breast cancer.
|
|
Academic Article
|
Colocalized delivery of rapamycin and paclitaxel to tumors enhances synergistic targeting of the PI3K/Akt/mTOR pathway.
|
|
Academic Article
|
MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit.
|
|
Academic Article
|
Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer.
|
|
Academic Article
|
Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent?) a VEGFR2/PDGFR?/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial.
|
|
Academic Article
|
MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitors.
|
|
Academic Article
|
Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agents.
|
|
Academic Article
|
Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors.
|
|
Academic Article
|
Epithelial to mesenchymal transition is associated with rapamycin resistance.
|
|
Academic Article
|
Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials.
|
|
Academic Article
|
Hepatocellular carcinoma: Where there is unmet need.
|
|
Academic Article
|
mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer.
|
|
Academic Article
|
Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials.
|
|
Academic Article
|
Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab.
|
|
Academic Article
|
Phase Ib/II Study of the Safety and Efficacy of Combination Therapy with Multikinase VEGF Inhibitor Pazopanib and MEK Inhibitor Trametinib In Advanced Soft Tissue Sarcoma.
|
|
Academic Article
|
Targeting TRK family proteins in cancer.
|
|
Academic Article
|
Identification of frequent somatic mutations in inflammatory breast cancer.
|
|
Academic Article
|
Co-occurring Genomic Alterations and Association With Progression-Free Survival in BRAFV600-Mutated Nonmelanoma Tumors.
|
|
Academic Article
|
Prior systemic treatment increased the incidence of somatic mutations in metastatic breast cancer.
|
|
Academic Article
|
Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer.
|
|
Academic Article
|
Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors.
|
|
Academic Article
|
HER kinase inhibition in patients with HER2- and HER3-mutant cancers.
|
|
Academic Article
|
Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma.
|
|
Academic Article
|
Strategic development of AZD1775, a Wee1 kinase inhibitor, for cancer therapy.
|
|
Academic Article
|
Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition.
|
|
Academic Article
|
A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations.
|
|
Academic Article
|
Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study.
|
|
Academic Article
|
Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation.
|
|
Academic Article
|
Impact of FDG PET Imaging for Expanding Patient Eligibility and Measuring Treatment Response in a Genome-Driven Basket Trial of the Pan-HER Kinase Inhibitor, Neratinib.
|
|
Academic Article
|
Targeting AKT for cancer therapy.
|
|
Academic Article
|
Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.
|
|
Academic Article
|
Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer.
|
|
Academic Article
|
Characteristics and Outcome of AKT1E17K-Mutant Breast Cancer Defined through AACR Project GENIE, a Clinicogenomic Registry.
|
|
Academic Article
|
Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations.
|
|
Academic Article
|
Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors.
|
|
Academic Article
|
Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial.
|
|
Academic Article
|
First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors.
|
|
Academic Article
|
Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations.
|
|
Academic Article
|
Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer.
|
|
Academic Article
|
Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer.
|
|
Academic Article
|
First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models.
|
|
Academic Article
|
Combined inhibition of DDR1 and CDK4/6 induces synergistic effects in ER-positive, HER2-negative breast cancer with PIK3CA/AKT1 mutations.
|
|
Academic Article
|
Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations.
|
|
Academic Article
|
Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma.
|
|
Academic Article
|
A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation.
|
|
Academic Article
|
Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results.
|
|
Academic Article
|
Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor-Positive Metastatic Breast Cancers.
|
|
Academic Article
|
Weight gain in patients with RET aberrant cancers treated with brain penetrant RET selective inhibitors.
|
|
Academic Article
|
Convergent MAPK pathway alterations mediate acquired?resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma.
|
|
Academic Article
|
Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma.
|
|
Academic Article
|
Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies.
|
|
Academic Article
|
RAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers: the RE-RAFFLE study.
|